- Home
- FLYW vs CNTA Comparison
FLYW vs CNTA Comparison
Compare FLYW & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYW
- CNTA
- Stock Information
- Founded
- FLYW 2009
- CNTA 2020
- Country
- FLYW United States
- CNTA United Kingdom
- Employees
- FLYW N/A
- CNTA N/A
- Industry
- FLYW Computer Software: Prepackaged Software
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- FLYW Technology
- CNTA Health Care
- Exchange
- FLYW Nasdaq
- CNTA Nasdaq
- Market Cap
- FLYW 2.2B
- CNTA 2.3B
- IPO Year
- FLYW 2021
- CNTA 2021
- Fundamental
- Price
- FLYW $20.13
- CNTA $17.16
- Analyst Decision
- FLYW Strong Buy
- CNTA Strong Buy
- Analyst Count
- FLYW 13
- CNTA 7
- Target Price
- FLYW $25.31
- CNTA $23.71
- AVG Volume (30 Days)
- FLYW 1.4M
- CNTA 705.7K
- Earning Date
- FLYW 11-07-2024
- CNTA 11-12-2024
- Dividend Yield
- FLYW N/A
- CNTA N/A
- EPS Growth
- FLYW N/A
- CNTA N/A
- EPS
- FLYW 0.16
- CNTA N/A
- Revenue
- FLYW $475,139,000.00
- CNTA $6,853,000.00
- Revenue This Year
- FLYW $23.63
- CNTA N/A
- Revenue Next Year
- FLYW $24.41
- CNTA N/A
- P/E Ratio
- FLYW $123.88
- CNTA N/A
- Revenue Growth
- FLYW 26.50
- CNTA N/A
- 52 Week Low
- FLYW $15.19
- CNTA $6.65
- 52 Week High
- FLYW $31.54
- CNTA $18.97
- Technical
- Relative Strength Index (RSI)
- FLYW 43.66
- CNTA 50.89
- Support Level
- FLYW $19.83
- CNTA $16.02
- Resistance Level
- FLYW $21.75
- CNTA $18.12
- Average True Range (ATR)
- FLYW 0.76
- CNTA 1.08
- MACD
- FLYW -0.26
- CNTA -0.08
- Stochastic Oscillator
- FLYW 8.82
- CNTA 41.42
About FLYW Flywire Corporation Voting
Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements namely a payments platform; a proprietary global payment network and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.